Longevity EMR of the Future • Peptides Pharmacy? • Loss of Goal-Directedness • Hers & Menopause

Issue 67: The front page of longevity medicine - curated by doctors, for doctors.

Hey Doc,

I find it fascinating that although innovation is everywhere (from AI to multi-omics to wearable sensors) healthcare still runs on legacy systems.
We’re surrounded by breakthroughs, yet most clinics still depend on EMRs built for billing, fax machines for communication, and phone calls for scheduling.

This is the innovation dilemma: when industries become so optimized around outdated models that they can’t evolve. Medicine is caught in what economists call technological lock-in: systems so complex, regulated, and interconnected that true reinvention feels impossible.

Longevity medicine gives us a chance to start fresh; to design an infrastructure that learns, adapts, and connects science with care in real time.
And that’s what makes this moment so exciting.

Healthy Sunday!

PS: Just finished a beautiful brunch with my family flying in from the Caribbean and friends stopping through from LA. Making time for the people who matter most feels incredible… a reminder to truly enjoy life while we can.

Dr. David Luu
Founder, Longevity Docs
www.longevitydocs.org

---

In this week newsletter:

• Cover Story: The Longevity EMR of the Future

• Buzz in the Chat: EMRs crisis • Peptides Pharmacy

• Research Radar: Aging as a Loss of Goal-Directedness • Clinical skills in the age of AI assistance

• Longevity in the News: Status symbol • Naked Mole Rats

• Longevity Intelligence: Hers & Menopause • Noninvasive Cancer Therapy

Each week, I try to explore one idea that could advance longevity medicine and hopefully support physicians in bringing it to life.

The Longevity EMR of the Future

We all feel it. The system just doesn’t work. So I decided to write about what should.

I feel you, doctors. I’ve been there too. We’ve all tried them, and yet no platform truly fits how we practice longevity medicine. We spend hours managing data instead of patients. And deep down, we all agree: EMRs weren’t designed for us.

They were built for insurance billing, not precision health management. They optimize for codes, not outcomes. And that’s why every longevity doctor I talk to ends up saying the same thing: “I’ve tested everything, nothing works.”

So I thought I’d write about my dream tech stack, what a true Longevity EMR of the future could look like if money, legacy systems, and bureaucracy weren’t in the way.

You can’t design what you don’t know

Most EMRs were built for transactional care by brilliant engineers who never operated a clinic or talked to a patient.
But our world is different. We focus on incredible patient experience, cash-pay care, and data-rich, continuously evolving protocols.

We integrate multi-omics, therapy protocols, continuous monitoring, and lifestyle data. We coach patients on everything from prediabetes management to VO₂ max optimization.
No billing system can capture all of that.

What longevity doctors need isn’t a new EMR. We need a longevity operating system that thinks and learns with us.

The future Longevity Operative System

If we could start from scratch, it would be open source, intelligent by default, and built for both doctors and patients, not one or the other.

Most B2B EMRs solve for physician workflow. The future must be B2B2C, bridging both sides of care.

It should learn automatically, adapt in real time, and understand context.
No more dropdowns and endless forms. Instead, imagine a prompt-first interface where we ask:
“Hey LOS, which patients are out of range today?”
“What therapies should we adjust right now?”

This isn’t science fiction. It’s design thinking, a clinical AI copilot that helps us interpret, act, and personalize faster.

And beyond data, it should act.
A marketplace that books therapies, ships peptides, and recommends interventions with transparent evidence scores based on collective clinical outcomes.

My dream longevity tech stack

For patients: Education and empowerment through evidence-based content, ambient AI coaching, and one unified dashboard that connects wearables, labs, and behavior, private with data ownership yet seamlessly shared with their doctor.

For doctors: The system integrates multi-omics biomarkers, imaging, protocols, and notes. AI scribes document visits, while protocol builders let us design and share evidence-based treatment stacks. Payment and analytics are built in, not bolted on.

For research: Every patient could voluntarily contribute anonymized data to a global longevity registry and be incentivized for it. An AI engine would learn from thousands of clinics, turning daily care into real-world research in partnership with health systems.

For community: A network where longevity physicians exchange insights, troubleshoot tough cases, and publish findings together. Our collective practice becomes our collective evidence base.

For trust & compliance: SOC2-grade security, transparent AI logic, and true data ownership by doctors and patients. No hidden algorithms, no public data leaks. More patient data sovereignty and transparency.

Longevity doctors don’t need another EMR.
They need an intelligent clinical ecosystem that mirrors how we actually practice longevity medicine, preventive, data-driven, and deeply human.

Every week, the Longevity Docs WhatsApp group feels like a front-row seat to the future of medicine. Here’s what had doctors buzzing:

EMR Crisis

• “I demoed at least six or seven before landing on Healthie and I’m starting to realize it may not be the right one for me.”

• “Maybe we should crowdfund within this group and create our own.”

• Multiple practitioners echoed the same frustration about Healthie, Peak, Vibrant, Canvas, “I don’t love it.”

The Problem
Most EMRs are built for primary care billing, not longevity medicine workflows. They can’t handle real-time wearable data, multi-biomarker tracking, longevity-focused protocols, or continuous monitoring.

Why It Matters
One physician broke it down: $2,000/month EMR + $30–50K annual SOC2 audit + dashboard tools + lab connectors = $54K+/year for an infrastructure that still doesn’t fit.

Key Takeaways

• Before signing a 5-year EMR contract, ask: “Can I export all data in standard formats?”

• Watch the innovators: Vibrant (weekly feature updates), Heads Up / Airia (dashboard model), Longevitix (AI synthesis layer).

• DIY isn’t cheaper. SOC2 compliance alone kills most “build-your-own” dreams.

---

Peptides Sourcing?

What Docs Are Saying

• “The market is flooded with low-cost peptides. Patients don’t know—or care—about quality differences anymore.”

• “I don’t have a set markup. My markup for BPC is less than for something like Tesa or ARA-290. It depends on your market and service cost.”

• “How is everyone pricing peptides? Are people keeping margin on the medications too?”

• “What are the real medico-legal ramifications of using non-FDA-approved peptides?”

• “There is still the issue of research vs compounded sources. Keep an eye out for the buccal strip delivery. Since it is oral, the research grade sources become less of a issue legally. And there are multiple companies that have new buccal absorption technology. And there may be research studies to verify bioavailability. Lot’s on the horizon for peptides!”

Most physicians admit to working with 6–8 different pharmacies (Nubioage, VPI, Brooksville, South Lake, ReviveRx, Empower, Pure, Progress), yet can’t clearly articulate the quality differences.
One doc put it bluntly: “Certain products I like better from each pharmacy.”

Why It Matters
Peptides are becoming commodities.
Two years ago, a 2–3x markup was common. Today, doctors are shifting to service-based pricing, higher consultation fees, lower medication margins, because patients won’t pay premiums for undifferentiated products.

Meanwhile, regulatory pressure is mounting. FDA rules around compounding are tightening. Compliance requirements for compounded drugs are stricter than off-label use (which remains legal for approved drugs). State-by-state variability compounds the confusion.

Key Takeaways

• Quality is unmeasured. Build a personal pharmacy scorecard tracking cost, consistency, response time, compliance clarity, and patient outcomes. Share anonymized insights with peers.

• Margins are shifting. Expect compression on medications. Build revenue through expertise, not markups.

• Know the law. Dr. T’s rule of thumb: For a compound to be legal, it must be FDA-approved, have a USP monograph, be on the FDA bulk/shortage list, and be used for its approved indication only.

• Simplify sourcing. Consolidate from 8+ to 2–3 trusted pharmacies to improve leverage, consistency, and compliance.

• Regulations vary. California is different than Texas. Review your state’s compounding rules before building your peptide protocols.

---

Join 500+ Longevity Docs Across 50 Countries

Longevity Docs is a highly vetted, invitation-only community for physicians shaping the future of longevity medicine. Apply online and connect 1:1 with our team

Each week, I highlight a few studies that caught our eyes and could shape the future of longevity medicine.

Aging as a Loss of Goal-Directedness

This model, published by Michael Levin, suggests a novel perspective on aging caused by loss of goal-directedness, with potentially significant implications for longevity research and regenerative medicine. Advanced Science

---

Preserving clinical skills in the age of AI assistance

How are clinicians to preserve core clinical skills in an era of algorithmic assistance? As artificial intelligence (AI) assumes a growing role in clinical practice, concern is mounting that off-loading clinical tasks and reasoning will lead to loss of skills (deskilling), adopting errors or bias from AI (mis-skilling), or failure to achieve competence. Lancet

---

The secreted metabolite sensor CtBP2 links metabolism to healthy lifespan

Consistently, serum CtBP2 levels decrease with age and are negatively associated with cardiovascular disease incidence in humans yet are elevated in individuals from families with a history of longevity. Together our findings define a CtBP2-mediated metabolic system with potential for future clinical applications. Nature Aging

I comb through the mainstream headlines, handpick the most relevant longevity stories.

Longevity: The great new status symbol

Longevity is no longer only about living longer. It’s become a cultural and economic symbol of power and access. El Pais

---

Scientists Explore the Mysterious Lives and Longevity Superpowers of Naked Mole Rats

The nearly hairless rodents are extremely resistant to cancer—and can live to be 37 years old. Smithsonian

---

Eric Verdin: 4 Science-Backed Habits That Could Help You Live Longer

Scientists now say they are getting closer to unlocking the secrets of longevity. Billions of dollars are being spent on an effort to find drugs and other therapies that could help people live healthier for longer. But what if the fountain of youth was already within our reach: everyday habits, backed by science, that could transform your health now? Time

---

Scientists Spot Blood Clue That May Reveal How Fast You Age

Researchers at the University of Tsukuba identified a protein called CtBP2 that may act as a biomarker for biological aging. Blood levels of CtBP2 decrease with age and are higher in individuals from long-lived families, suggesting it plays a role in metabolism, healthspan, and systemic aging. TechnologyNetwork

Every week, I track the biggest moves in longevity: new funding rounds, partnerships, product launches, and key hires.

Hims & Hers to Offer Treatments for Menopause, Perimenopause

Hims & Hers has launched a new women’s health specialty focused on menopause and perimenopause care, expanding its digital platform to offer personalized treatment plans for women. The service includes access to licensed providers, educational support, and prescription options such as estradiol and progesterone. WSJ

---

HistoSonics raises $250M to expand use of noninvasive cancer therapy

The company raised money from Bezos Expeditions, Thiel Bio and other investors to fund the commercial and clinical expansion of its technology. MedetechDive

Longevity Docs AI/Tech Mastermind

New York City & Virtual | January 17, 2026

Longevity Docs Summit Cannes

Cannes, France | June 10-11, 2026

Longevity Docs Around the World

Meet us at the following events:

• Riyadh · October 24–26 — Zenos Health Summit

• New York · October 30 — Galien Patient Summit

• Miami · November 12 — Longevity Docs Table

• Novato · December 6-8 — Longevity Clinic Roundtable

• Vegas · January 6-9 — CES

Conferences Calendar

• Health Optimization Medicine Symposium: Boulder, October 17-18

• Biomarkers of Aging: Boston, October 20-21, 2025

• Eudemonia: Palm Beach, November 13-16

• A4M: Las Vegas, December 12-13

Why every doctor should be a longevity doctor.

The Movement

Longevity Docs is the world’s leading collective of physicians advancing longevity medicine through education, clinical research, advisory, and exclusive experiences. With over 400 members in 50+ countries, we’re building the global infrastructure for evidence-based, personalized longevity care.

Why “Longevity Docs”?

Because we believe longevity is not a specialty — it’s a human right.

The future of medicine is proactive, not reactive. It's interdisciplinary, not isolated. It’s collaborative, data-driven, and deeply human. And it starts with us — the physicians who dare to redefine what care looks like across the decades of a patient’s life.

“Longevity Docs” isn’t just a name. It’s a statement of purpose.

---

Our Ecosystem

• Physician Network
  A trusted global collective of longevity-focused doctors exchanging protocols, referrals, and real-world clinical outcomes.

• Education & Certification
  Earn your Certified Longevity Doctor™ designation through our advanced curriculum, live masterclasses, and continuous learning tracks.

• Decentralized Research
  Lead or participate in multicenter clinical trials and patient registries, accelerating evidence generation for healthspan optimization.

• Strategic Advisory
  We partner with vetted longevity companies, life-science, tech, and clinics to help them grow.

• Global Events & Experiences
  Access exclusive gatherings like the NYC Mastermind and the Cannes Longevity Summit & Awards

---

Who It’s For

• Doctors → Join the club, get certified, grow your practice

• Health Systems → Implement clinical longevity programs

• Brands & Startups → Validate products, find advisors, run trials

• Investors → Gain early access to insights, doctors, and deal flow

We’re not just witnessing the transformation of longevity medicine we’re building it. Together.

---

Subscribe to the Longevity Docs Newsletter

Stay connected with the backstage of the Longevity Docs community, a network of over 500 physicians spanning 50 countries, united in our mission to democratize longevity medicine. Explore the latest in evidence-based longevity care, gain exclusive access to physician insights, and join us in shaping the future of this transformative field.

---

Newsletter Disclaimer:

The content shared in this newsletter, including the "Buzz in the Chat" section, is for educational purposes only. It is derived from peer-to-peer conversations among physicians within the Longevity Docs community and is intended to inform and engage our network of doctors.

Please note that these discussions do not reflect the official position of Longevity Docs and are not to be interpreted as medical advice or recommendations. The insights and opinions shared are those of individual physicians and are provided as part of our mission to foster collaborative learning and dialogue among healthcare professionals.

We encourage all readers to consult qualified healthcare professionals for personalized medical advice and to evaluate any medical information in the context of their clinical expertise and patient needs.